Cargando…
Advanced Liver Fibrosis Correlates With Impaired Efficacy of Pfizer‐BioNTech COVID‐19 Vaccine in Medical Employees
The Pfizer‐BioNTech coronavirus disease 2019 (COVID‐19) vaccine has been offered to nonallergic ≥16‐year‐old Israeli adults since December 19, 2020. Data regarding factors associated with vaccine ineffectiveness are limited. The aim of this study is to assess the impact of hepatic fibrosis on the ef...
Autores principales: | Shafrir, Asher, Amer, Johnny, Hakimian, David, Milgrom, Yael, Massarwa, Muhammad, Hazou, Wadi, Imam, Ashraf, Khalaileh, Abed, Safadi, Rifaat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110948/ https://www.ncbi.nlm.nih.gov/pubmed/35147300 http://dx.doi.org/10.1002/hep4.1901 |
Ejemplares similares
-
SARS-CoV-2 vaccine alleviates disease burden and severity in liver transplant recipients even with low antibody titers
por: Khalaileh, Abed, et al.
Publicado: (2023) -
Weaker SARS-CoV-2 vaccine responses in nonalcoholic fatty liver disease with advanced liver fibrosis
por: Hakimian, David, et al.
Publicado: (2023) -
Myocarditis with Pfizer-BioNTech's COVID-19 vaccine in Israel
Publicado: (2021) -
Thrombocytopenia with Pfizer-BioNTech or Moderna COVID-19 vaccines
Publicado: (2021) -
Pfizer-BioNTech COVID-19 vaccine safe in children
Publicado: (2022)